ClinicalTrials.gg
Active, not recruitingNCT07000123AZURE-LDLUpdated Aug 11, 2026

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

A Phase 3 interventional study of AZD0780 and Placebo in Cardiovascular Disease, sponsored by AstraZeneca. Active, not recruiting at 404 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study.

The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Read the detailed description

This is a randomised, double-blind, placebo-controlled, parallel-group Phase III study to evaluate the effect on the reduction of LDL-C and the safety and tolerability of AZD0780 versus placebo, administered as xx mg once daily orally, on top of a high intensity lipid-lowering regimen. The target population is adults ≥ 18 years of age with LDL-C ≥ 55 mg/dL and history of clinical ASCVD or ≥ 70 mg/dL and at risk for a first ASCVD event.

The study will be conducted at approximately 470 centres in approximately 21 countries.

The screening period is up to 14 days (and may be conditionally extended), starts at the date of signed informed consent, and ends on the day before the randomisation visit. Participants will be randomised in a 1:1 ratio to either AZD0780 or placebo for a treatment period of 52 weeks and a 10-day safety follow-up. Those randomised to the AZD0780 group will receive AZD0780 xx mg orally once daily during the treatment period, while those in the placebo group will receive matching placebo. The study will include approximately 2800 randomised participants. An independent data monitoring committee will, on a regular basis, review accumulating data from the study, evaluate adverse effects of the IMP, and make recommendations regarding whether to halt or modify the study.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Low-Density Lipoprotein Cholesterol
  • Atherosclerotic Cardiovascular Disease
03

In context

Cardiovascular Diseases

5,372 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 3,103 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age at the time of signing the ICF
  • History of clinical ASCVD or at risk for a first ASCVD event:

    1. Clinical ASCVD is defined as MI, stable or unstable angina, coronary or other arterial revascularisation, ischaemic stroke, or peripheral artery disease.
    2. A participant is considered at risk for a first ASCVD event if the participant has one or more of the following conditions: atherosclerotic vascular disease (≥ 50% stenosis in ≥ 2 coronary artery territories or in ≥ 2 vascular beds [coronary, carotid, lower extremity], diagnosed by any imaging modality), diabetes mellitus, hypertension, cigarette smoking, chronic kidney disease (moderate to severe stage), or obesity. Investigators can also use the ACC/AHA or ESC or other relevant national clinical guidelines for risk assessment to identify participants with at least moderate risk for ASCVD.
  • Fasting serum LDL-C by central laboratory at screening as follows: LDL-C ≥ 55 mg/dL (≥ 1.4 mmol/L) in participants with clinical ASCVD or ≥ 70 mg/dL (≥ 1.8 mmol/L) in participants without clinical ASCVD but at risk for a first ASCVD event
  • Participants should receive a background lipid lowering regimen anticipated to achieve at least a \~50% reduction in LDL-C. Except in cases of intolerance, the regimen should include a high intensity statin therapy or lower intensity statin therapy in combination with an oral agent with proven outcome benefit (eg, ezetimibe and/or bempedoic acid).

Thus, the background lipid-lowering therapy must consist of one of the following:

- A high intensity LDL lowering regimen

(i) A high intensity statin regimen, as defined by country specific guidelines OR: (ii) A lower intensity statin regimen in combination with ezetimibe and/or bempedoic acid :

OR:

- A maximum tolerated statin regimen - Oral combination therapy with ezetimibe and/or bempedoic acid is strongly recommended.

Participants must achieve a stable background lipid lowering therapy > 28 days before screening.

Exclusion criteria

Exclusion criteria:

  • Homozygous familial hypercholesterolaemia, known diagnosis of HeFH, LDL apheresis or plasma apheresis within 12 months prior to screening, or any other underlying known disease or condition that may interfere with interpretation of the clinical study results as judged by the Investigator.
  • Any of the following laboratory values at screening:

    • Calculated \< 15 mL/min/1.73 m2
    • or ALT > 3 ×
    • TBL > 2 × ULN (except for patients with Gilberts syndrome, where TBL 3 × ULN is acceptable provided direct \< 1.5 × ULN)
    • Fasting triglycerides ≥ 400 mg/dL (≥ 4.52 mmol/L)
    • Creatine kinase > 5 × ULN
    • Urine albumin-to-creatinine ratio ≥ 500 mg/g
  • Uncontrolled type 2 diabetes mellitus defined as ≥ 9.5% at screening
  • Inadequately treated hypothyroidism defined as TSH > 1.5 ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening
  • Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months prior to screening or planned use during the study.
  • Use of gemfibrozil within 1 week prior to screening or planned use during the study.
  • Use of PCSK-9 inhibitors: evolocumab/alirocumab within 12 weeks of the screening visit or planned use during the study or inclisiran within 18 months of the screening visit or planned use during the study. Any other approved PCSK-9 inhibitor use within 5 half-lives prior to the screening visit or planned use during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
3,103 participants (actual)

Study arms

  • Experimental
    AZD0780

    Participants will receive daily oral dose of AZD0780

    Drug: AZD0780

  • Placebo comparator
    Placebo

    Participants will receive daily oral dose of placebo

    Drug: Placebo

Interventions

  • Participants will receive daily oral dose of AZD0780

  • DrugPlacebo

    Participants will receive daily oral dose of placebo

06

What researchers measure

Primary outcomes

  1. Relative change in LDL-C from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks

    Time frame: Baseline - 12 weeks

Secondary outcomes

  1. Relative change in LDL-C from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks in patients on background statin therapy

    Time frame: Baseline - 12 weeks

  2. Indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on the probability of LDL-C \< 70 mg/dL at 12 weeks in patients with baseline LDL-C ≥ 70 mg/dL

    Time frame: Baseline - 12 weeks

  3. Indicator for LDL-C < 55 mg/dL (< 1.4 mmol/L) at 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on the probability of LDL-C \< 55 mg/dL at 12 weeks

    Time frame: Baseline - 12 weeks

  4. Relative change in LDL-C from baseline to 28 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 28 weeks

    Time frame: Baseline - 28 weeks

  5. Relative change in LDL-C from baseline to 52 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 52 weeks

    Time frame: Baseline - 52 weeks

  6. Relative change in Apo B from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on apolipoprotein (Apo) B at 12 weeks

    Time frame: Baseline - 12 weeks

  7. Relative change in non-HDL-C from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on non-high-density lipoprotein cholesterol (HDL-C) at 12 weeks

    Time frame: Baseline - 12 weeks

  8. Relative change in total cholesterol from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on total cholesterol at 12 weeks

    Time frame: Baseline - 12 weeks

  9. Relative change in Lp(a) from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on lipoprotein(a) (Lp\[a\]) at 12 weeks

    Time frame: Baseline - 12 weeks

07

Study locations

404 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Irondale, Alabama 35210, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Gilbert, Arizona 85296, United States
  • Research Site
    Phoenix, Arizona 85014, United States
  • Research Site
    Sun City West, Arizona 85375, United States
  • Research Site
    Garden Grove, California 92844, United States
  • Research Site
    Gardena, California 90247, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    West Hills, California 91307, United States
  • Research Site
    Hamden, Connecticut 06517, United States
  • Research Site
    Boca Raton, Florida 33434, United States
  • Research Site
    Hallandale, Florida 33009, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Inverness, Florida 34452, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    New Port Richey, Florida 34653, United States
  • Research Site
    Orlando, Florida 32807, United States
  • Research Site
    Pembroke Pines, Florida 33029, United States
  • Research Site
    Seminole, Florida 33777, United States
  • Research Site
    Tampa, Florida 33625, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Peachtree Corners, Georgia 30092, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Winfield, Illinois 60190, United States
  • Research Site
    Evansville, Indiana 47714, United States
  • Research Site
    Evansville, Indiana 47715, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Ames, Iowa 50010, United States
  • Research Site
    El Dorado, Kansas 67042, United States
  • Research Site
    Wichita, Kansas 67218, United States
  • Research Site
    Owensboro, Kentucky 42301, United States
  • Research Site
    Hammond, Louisiana 70403, United States
  • Research Site
    Kenner, Louisiana 70065, United States
  • Research Site
    Lafayette, Louisiana 70508, United States
  • Research Site
    Lake Charles, Louisiana 70601, United States
  • Research Site
    Shreveport, Louisiana 71105, United States
  • Research Site
    Zachary, Louisiana 70791, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21229, United States
  • Research Site
    Beltsville, Maryland 20705, United States
  • Research Site
    Potomac, Maryland 20854, United States
  • Research Site
    Chesterfield, Missouri 63005, United States
  • Research Site
    Jefferson City, Missouri 65109, United States
  • Research Site
    Kansas City, Missouri 64131, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Buffalo, New York 14217, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    The Bronx, New York 10451, United States
  • Research Site
    Durham, North Carolina 27701, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Hickory, North Carolina 28601, United States
  • Research Site
    Morganton, North Carolina 28655, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Rocky Mount, North Carolina 27804, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Statesville, North Carolina 28625, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    Blue Ash, Ohio 45242, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Lima, Ohio 45805, United States
  • Research Site
    Camp Hill, Pennsylvania 17011, United States
  • Research Site
    Horsham, Pennsylvania 19044, United States
  • Research Site
    Philadelphia, Pennsylvania 19114, United States
  • Research Site
    West Chester, Pennsylvania 19380, United States
  • Research Site
    Anderson, South Carolina 29621, United States
  • Research Site
    Fort Mill, South Carolina 29707, United States
  • Research Site
    Mauldin, South Carolina 29662, United States
  • Research Site
    Mt. Pleasant, South Carolina 29464, United States
  • Research Site
    North Charleston, South Carolina 29405, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Knoxville, Tennessee 37849, United States
  • Research Site
    Knoxville, Tennessee 37912, United States
  • Research Site
    Knoxville, Tennessee 37938, United States
  • Research Site
    Beaumont, Texas 77706, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77043, United States
  • Research Site
    Humble, Texas 77338, United States
  • Research Site
    Irving, Texas 75061, United States
  • Research Site
    Katy, Texas 77450, United States
  • Research Site
    Mesquite, Texas 75149, United States
  • Research Site
    Paris, Texas 75462, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Marcos, Texas 78666, United States
  • Research Site
    Sugar Land, Texas 77478, United States
  • Research Site
    Charlottesville, Virginia 22911, United States
  • Research Site
    Hampton, Virginia 23666, United States
  • Research Site
    Norfolk, Virginia 23504, United States
  • Research Site
    Suffolk, Virginia 23435, United States

Showing the first 100 of 404 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's planned 19 months is below that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 2, 2025
StartActual
May 28, 2025
Primary completionEst.
Jan 11, 2027
CompletionEst.
Jan 11, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07000123
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 2, 2025
Start date
May 28, 2025
Primary completion
Jan 11, 2027 (estimated)
Completion
Jan 11, 2027 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion